Improvement of End-of-Synthesis Radiochemical Purity of <sup>177</sup>Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization
Background: Radiochemical purity is a key criterion for the quality of radiopharmaceuticals used in clinical practice. The joint improvement of analytical methods capable of identifying related radiochemical impurities and determining the actual radiochemical purity, as well as the improvement of sy...
Saved in:
| Main Authors: | Anton Larenkov, Iurii Mitrofanov, Marat Rakhimov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/16/12/1535 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Features and Practical Aspects of Radiochemical Purity Determination of Receptor-Specific Lu-177 Radiopharmaceuticals as Exemplified by [<sup>177</sup>Lu]Lu–PSMA-617
by: A. A. Larenkov, et al.
Published: (2022-12-01) -
The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01) -
Hematological Side Effects of <sup>177</sup>Lu-DOTA-TATE Therapy in Patients with NENs
by: Luciano Carideo, et al.
Published: (2024-12-01) -
Stability in the production and transport of 177Lu labelled PSMA
by: Cristian Antonio Wieczorek Villas Boas, et al.
Published: (2021-03-01) -
Efficacy of <sup>177</sup>Lu-PSMA-617 Therapy in mCRPC Patients with Liver Metastases: Insights into Survival Outcomes and Predictors of Response
by: Ebuzer Kalender, et al.
Published: (2025-02-01)